Clofibrate (tradename Atromid-S) is a fibrate. It is a lipid lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It is proved that it can increase the level of HDL as well.

PropertyValue
dbpedia-owl:Drug/atcPrefix
  • C10
dbpedia-owl:Drug/atcSuffix
  • AB01
dbpedia-owl:Drug/boilingPoint
  • 148
dbpedia-owl:Drug/casNumber
  • 637-07-0
dbpedia-owl:Drug/drugbank
  • APRD00879
dbpedia-owl:Drug/iupacName
  • ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
dbpedia-owl:Drug/pubchem
  • 2796
dbpedia-owl:atcPrefix
  • C10
dbpedia-owl:atcSuffix
  • AB01
dbpedia-owl:boilingPoint
  • 148
dbpedia-owl:casNumber
  • 637-07-0
dbpedia-owl:drugbank
  • APRD00879
dbpedia-owl:iupacName
  • ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
dbpedia-owl:pubchem
  • 2796
dbpedia-owl:thumbnail
dbpprop:abstract
  • Clofibrate (tradename Atromid-S) is a fibrate. It is a lipid lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It is proved that it can increase the level of HDL as well. Can induce SIADH (syndrome of inappropriate secretion of antidiuretic hormone ADH or otherwise called vasopressin) The World Health Organization Cooperative Trial on Primary Prevention of Ischaemic Heart Disease using Clofibrate to lower serum cholesterol observed that there was excess mortality in the clofibrate-treated group despite successful cholesterol lowering (47% more deaths during treatment with clofibrate and 5% after treatment with clofibrate) than the non-treated high cholesterol group. These deaths were due to a wide variety of causes other than heart disease, and remain "unexplained."
  • El clofibrato es una sustancia derivada del ácido fíbrico, que se utiliza para disminuir los niveles de triglicéridos en sangre. Al igual que otros fibratos activa el factor de transcripción PPAR-α. Esto promueve la oxidación de ácidos grasos y estimula la actividad LPL, lo que reduce los TG, y aumenta la síntesis de apoproteínas de las HDL, lo que incrementa las cifras de cHDL. Este fármaco está cayendo en desuso por las ventajas que tienen otros fármcos de la misma familia sobre él.
  • Le clofibrate est une molécule hypolipémiante appartenant aux fibrates. Il fait augmenter la synthèse de Lipoprotéine Lipase, entrainant de ce fait une diminution de la concentration de VLDL et LDL De plus, il inhibe la synthèse d'acétyl-CoA (donc baisse de la synthèse de TG) et la HMG-CoA réductase (et donc la synthèse de cholestérol)
  • O clofibrato (C12H15ClO3) é um fármaco que diminui as taxas de colesterol e triglicerídios do sangue. Essa classe de drogas reduzem em até 50% as VLDL,e, consequentemente, os triglicerídios, com modesta redução na LDL. Aumento da HDL ocorre em torno de 10%. Os seus mecanismos de ação não são completamente compreendidos. Essas drogas estimulam a lipase lipoproteica, aumentando a hidrólise de triglicerídios nos quilomícrons e nas VLDL. Elas provovelmente reduzem a produção de VLDL hepática, aumentando sua recaptação. Além dessas ações, os fibratos também reduzem o fibrinogênio plasmático e melhoram a tolerância à glicose, embora não se saiba se esses efeitos são clinicamente importantes (1).
dbpprop:atcPrefix
  • C10
dbpprop:atcSuffix
  • AB01
dbpprop:boilingHigh
  • 150 (xsd:integer)
dbpprop:boilingPoint
  • 148 (xsd:integer)
dbpprop:c
  • 12 (xsd:integer)
dbpprop:casNumber
  • 0637-07-00
dbpprop:cl
  • 1 (xsd:integer)
dbpprop:drugbank
  • APRD00879
dbpprop:eliminationHalfLife
  • Highly variable; average 18–22 hours. Prolonged in renal failure
dbpprop:excretion
  • Renal, 95 to 99%
dbpprop:h
  • 15 (xsd:integer)
dbpprop:hasPhotoCollection
dbpprop:iupacName
  • ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
dbpprop:legalUs
  • Rx-only
dbpprop:metabolism
dbpprop:molecularWeight
  • 242.698 g/mol
dbpprop:o
  • 3 (xsd:integer)
dbpprop:pregnancyAu
  • B1
dbpprop:pregnancyUs
  • C
dbpprop:proteinBound
  • Variable, 92–97% at therapeutic concentrations
dbpprop:pubchem
  • 2796 (xsd:integer)
dbpprop:routesOfAdministration
  • Oral
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • Clofibrate (tradename Atromid-S) is a fibrate. It is a lipid lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It is proved that it can increase the level of HDL as well.
  • El clofibrato es una sustancia derivada del ácido fíbrico, que se utiliza para disminuir los niveles de triglicéridos en sangre. Al igual que otros fibratos activa el factor de transcripción PPAR-α. Esto promueve la oxidación de ácidos grasos y estimula la actividad LPL, lo que reduce los TG, y aumenta la síntesis de apoproteínas de las HDL, lo que incrementa las cifras de cHDL.
  • Le clofibrate est une molécule hypolipémiante appartenant aux fibrates. Il fait augmenter la synthèse de Lipoprotéine Lipase, entrainant de ce fait une diminution de la concentration de VLDL et LDL De plus, il inhibe la synthèse d'acétyl-CoA (donc baisse de la synthèse de TG) et la HMG-CoA réductase (et donc la synthèse de cholestérol)
  • O clofibrato (C12H15ClO3) é um fármaco que diminui as taxas de colesterol e triglicerídios do sangue. Essa classe de drogas reduzem em até 50% as VLDL,e, consequentemente, os triglicerídios, com modesta redução na LDL. Aumento da HDL ocorre em torno de 10%. Os seus mecanismos de ação não são completamente compreendidos. Essas drogas estimulam a lipase lipoproteica, aumentando a hidrólise de triglicerídios nos quilomícrons e nas VLDL.
rdfs:label
  • Clofibrate
  • Clofibrato
  • Clofibrate
  • Clofibrato
owl:sameAs
skos:subject
foaf:depiction
foaf:page
is dbpprop:metabolism of
is dbpprop:redirect of
is owl:sameAs of